Form 4: Phibro CEO Sells $192K in Stock Under 10b5-1 Plan

Phibro Animal Health Corp's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold 4,808 shares of Class A Common Stock for approximately $192,760 through a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corp, and BFI Co., LLC, a 10% owner controlled by Bendheim, reported sales of Class A Common Stock.
• On December 8, 2025, 3,520 shares were sold at a weighted average price of $40.0618, with prices ranging from $40.00 to $40.195.
• On December 9, 2025, an additional 1,288 shares were sold at a weighted average price of $40.1889, with prices ranging from $40.01 to $40.34.
• The total number of shares sold across both transactions was 4,808.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Following these transactions, BFI Co., LLC indirectly holds 44,952 shares, and Jack Bendheim directly holds 16,840 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on undisclosed negative information. It's a routine disclosure for personal financial planning.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and non-discretionary transaction rather than an immediate reaction to new information.

Negatives

• An insider, who is also the President and CEO and a 10% owner, selling shares could be perceived negatively by some investors, potentially signaling a lack of confidence or a need for liquidity.

Management Comments

• The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the 'Issuer'), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.
• Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing reports an insider stock sale, which is a routine disclosure for publicly traded companies. It does not provide specific insights into broader industry trends within the animal health sector but reflects individual executive financial planning.

Related Party Transactions

• Jack Bendheim, President and CEO, and BFI Co., LLC, a 10% owner controlled by Bendheim, engaged in sales of company stock. This is a related party transaction as it involves a key executive and an entity under his control.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns. The total value of the sale is relatively small compared to the company's market capitalization, so the direct impact on share price is likely minimal.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider trading report.

Key Dates

Recommendation

The insider sale by CEO Jack Bendheim, while a disposition of shares, was executed under a pre-arranged 10b5-1 trading plan. This suggests the transaction is part of a personal financial strategy rather than a reaction to new material non-public information. Given the relatively small volume of shares sold compared to the company's overall market, and the pre-planned nature, this event alone does not warrant a change in investment thesis. Investors should continue to hold based on the company's fundamental performance and broader market conditions, rather than this routine insider disclosure.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO Stock Sale, Animal Health